The prototype for targeting BRAF V600 lesions is cutaneous melanoma, where BRAF mutations occur in 40–60% and the single-agent selective BRAF-inhibitor, vemurafenib, was approved a decade ago [74]. This evidence concerns the gene BRAF and cutaneous melanoma.